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Available online 11 February 2016The Genea080 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying compound heterozygousmutations in the NEB gene, exon 55 deletion & c.15110dupA, indic-
ative of NemalineMyopathy Type 2 (NEM2). Following ICM outgrowth on inactivated human feeders, karyotype
was conﬁrmed as 46, XY and STR analysis demonstrated a male allele pattern. The hESC line had pluripotent cell
morphology, 90% of cells expressed Nanog, 95% Oct4, 54% Tra1-60 and 99% SSEA4 and gave a PluriTest
Pluripotency score of 32.08, Novelty of 1.3. The cell line was negative for Mycoplasma and visible contamination.
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Cell line derivation
The zona pellucida of a blastocyst stage human embryo was
removed using a small blade. The thawed embryo was plated
whole onto mitomycin C inactivated human feeders (Detroit 551
HFF — 90,000/well in 4-well) in 20% knock out serum in standard
hESC culture medium (Amit et al., 2000) with 20 ng/mL Fgf2.
CGH karyotyping and STR proﬁling was performed at the ﬁrst
cryobanking step from ICM outgrowths maintained on feeders.
Cells were then enzymatically passaged as single cells in M2
pluripotent cell maintenance medium (Genea Biocells) and CGH/
karyotyping repeated, immunoﬂuorescent pluripotent marker stain-
ing, PluriTest and sterility testing performed.Genetic analysis
1. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 6; CGH was used to screen targeted regions of
the genome for gains and losses associated with chromosomal
imbalances such as aneuploidy, deletions and duplications. CGH
was performed using SurePrint G3 microarrays (8 × 60 K format)
which were scanned with the Agilent Scanner C and analysed
using GenomicWorkbench Standard Edition 5.0 software (Agilent
Technologies).
2. DNA Proﬁling: Passage 5; DNA ‘ﬁngerprinting’ was performed
using the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied
Biosystems #4322288) to provide permanent genetic identiﬁca-
tion of the cell lines. https://www.thermoﬁsher.com/order/
catalog/product/4322288.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea080 (passage 6) reporting amale cell line andno abnormal-
ities detected.
CGH summary
Sample name Genea080p6
Date reported 12th February 2014
Hybridisation balance Balanced hybridisation was observed for all chromosomes,
relative to reference DNA
Copy number change No copy number changes N400 kb were detected
Interpretation Male cell line — no abnormalities detected
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1. Immunoﬂuorescence: Passage 9 (7 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. PluriTest: Passage 13 (11 on feeders, 2 enzymatic); RNAwas collected
and subjected to a PluriTest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
Sterility testing
1. Mycoplasma: Passage 9 (7 on feeders, 2 enzymatic); testing was
performed as per manufacturer's instructions using the MycoAlert
Mycoplasma Detection Kit from LONZA.
2. Microbial contamination: testing was performed in conjunction with
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal orTable 2
STR proﬁle; Genea080 (passage 5) demonstrating male allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S31
GENEA080_p5 11, 13 28, 30.2 8, 12 10, 11 15, 16 8, 9.3 11, 12
Fig. 1. Pluripotency validation of Genea080. A) Immunoﬂuorescent staining (10×) of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest pluripotency (leyeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.
Veriﬁcation and authentication
Ethics/consents: Ethics approval for the project (‘Derivation of
human embryonic stem cells from embryos identiﬁed through pre-
implantation genetic diagnosis to be affected by known genetic condi-
tions’)was obtained from theGenea Ethics Committee on 13 September
2005. Excess ART embryos were fully consented for stem cell derivation
by all responsible people through an informed consent process (signed
de-identiﬁed consent form can be provided upon request). Donors have
received no payment or ﬁnancial beneﬁts for their donation. Genea080
has been derived froma donated, fully commercially consented embryo,
originally created by assisted reproduction technology (ART) for
the purpose of procreation. The embryo was identiﬁed through pre-
implantation genetic diagnosis to be affected by a genetic mutation
and was declared excess to reproductive needs. Derivation was per-
formed under Australian National Health andMedical Research Council
(NHMRC) licence 309710. This licence was issued to GENEA on 7 May
2007. More information about the licence can be obtained from the
NHMRC webpage at http://www.nhmrc.gov.au/health-ethics/human-
embryos-and-cloning/database-licences-authorising-use-excess-art-
embryos.
PGD analysis conclusion: Mutation; Compound heterozygous exon
55 deletion & c.15110dupA in NEB gene. Family tree; both parents are
carriers. Nemaline Myopathy 2 (NEM2) affected.
Morphology: The derived stem cell line, Genea080, morphologically
displays adherent monolayer of compact cells in well-deﬁned colonies
with high nuclear to cytoplasmic ratio and prominent nucleoli.
Genetic analysis: The cell line has been karyotype tested by CGH
(Table 1, Supplementary Fig. 1), which demonstrated 46, XY karyotype,7 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
9, 12 17, 20 14, 14.2 15, 17 8, 9 12, 13 12, 13 22, 24
t cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 9, 2
ft) and novelty (right) scores with Genea080 (passage 13, 2 enzymatic) outlined in black.
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nosis (PGD). Analysis of STR markers showed allele pattern consistent
with male genotype (Table 2, Supplementary Fig. 2).
Pluripotency: GENEA080 is pluripotent by;
1. Immunoﬂuorescencewith 90%Nanog positive, 95%Oct4 positive, 54%
Tra1-60 positive and 99% SSEA4 positive (Fig. 1A, quantiﬁed in 1B).
2. PluriTest with a Pluripotency score of 32.08 and Novelty score of 1.3
(Fig. 1C).
Sterility: The cell line is tested and found negative for Mycoplasma
and any visible contamination (Supplementary Fig. 3).Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.016.
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